Genome-Wide CRISPR Screens Identify PARP Inhibitor Response in Prostate Cancer
A new study informed use of PARP inhibitors beyond BRCA1/2-deficient tumors and reevaluated biomarkers for PARP inhibition in prostate cancer.
Read MorePosted by Andy Lundin | Apr 4, 2023 | Amplification Technologies, Prostate |
A new study informed use of PARP inhibitors beyond BRCA1/2-deficient tumors and reevaluated biomarkers for PARP inhibition in prostate cancer.
Read MorePosted by Andy Lundin | Apr 4, 2023 | Cardiovascular, Kidney Disease |
A new proteomic risk model for cardiovascular disease was found to be more accurate than current methods of measuring cardiac risk
Read MorePosted by Andy Lundin | Mar 30, 2023 | Prostate |
A rapid test for advanced prostate cancer can quickly identify people with “actionable” gene variants eligible for new targeted therapies.
Read MorePosted by Andy Lundin | Mar 24, 2023 | Cancer |
A new study describes how we could better time when patients are tested for cancer to improve diagnostic accuracy.
Read MorePosted by Andy Lundin | Mar 24, 2023 | Cancer |
Using artificial intelligence, researchers have discovered how to screen for genetic mutations in cancerous brain tumors in under 90 seconds.
Read More